Posted by rob on March 5, 2011 under Uncategorized | 
Chronic myelogenous leukemia with mild basophilia as the predominant manifestation at presentation.
Intern Med. 2011;50(5):501-2
Authors: Yasuda H, Aritaka N, Ando J, Hirama M, Komatsu N, Hirano T
Chronic myelogenous leukemia (CML) is a clonal hematological malignancy typically presenting with basophilia and massive proliferation of differentiating myeloid cells. We report an atypical case of CML in which mild basophilia was the sole manifestation at presentation, and the condition persisted for 27 months with no sign of progression. This case reconfirms the importance of basophilia as a clinical manifestation of CML, and BCR-ABL FISH analysis should always be applied to cases of basophilia, even when the basophilia is modest and no other features of CML are present.
PMID: 21372467 [PubMed - in process]
More
Posted by rob on under Uncategorized |
Two Novel Alkaloids from the Stem of Saprosma hainanense and Their Cytotoxic Activities in Vitro.
Chem Pharm Bull (Tokyo). 2011;59(3):338-40
Authors: Wang L, Chen GY, Han CR, Yuan Y, Yang B, Zhang Y, Wang J, Zhong XQ, Huang X
Two novel alkaloids, saprosmine A (1) and saprosmine B (2), were isolated from the stem of Saprosma hainanense MERR., along with five known alkaloids: marcanine A (3); cleistopholine (4); 4-methoxycarbonyl-5,10-benzogquinolinequinone (5); liriodenine (6); and quinoline (7). The chemical structures were established on the basis of extensive spectroscopic (IR, 1D-NMR, 2D-NMR, MS) data analysies and by comparison with spectroscopic data reported in the literature. Compounds 1 to 6 were evaluated for in vitro cytotoxic activities against the SPC-A-1 (human lung cancer), BEL-7402 (human hepatocellular carcinoma), SGC-7901 (human gastric cancer), and K-562 (human myelogenous leukaemia) cancer cell lines. Compounds 1 and 2 exhibited weak cytotoxic activities against K-562 cells. Compounds 3 and 5 showed cytotoxic activities against all four cancer cell lines.
PMID: 21372415 [PubMed - in process]
More
Posted by rob on under Uncategorized |
Discontinuation of imatinib may be possible in chronic myelogenous leukemia.
CA Cancer J Clin. 2011 Mar 3;
Authors: Barton MK
PMID: 21372196 [PubMed - as supplied by publisher]
More
Posted by rob on under Uncategorized |
LITTLE ROCK, Ark. – In an opinion entered Feb. 17, the Arkansas Supreme Court affirmed a verdict against the parents of a child diagnosed with chronic myelogenous leukemia who allege that exposure to organic arsenic from chicken litter spread on farm fields caused the cancer (Mary E. Green, et al. v. George’s Farm Inc, et al., No. 10-26; Ark. Sup.; 2011 Ark. LEXIS 65; See 5/20/08, Page 4).
Full story on lexis.com (Source: LexisNexis® Mealey’s™ Emerging Toxic Torts Legal News)
More
Posted by rob on under Uncategorized |
Abstract Molecular monitoring is a key component of the management of patients with chronic myeloid leukemia. The current recommendation
is that molecular monitoring be performed in place of cytogenetic assessment when a major molecular response (MMR) is achieved.
With the more potent kinase inhibitors nilotinib and dasatinib now approved as front-line therapy, more patients will achieve
an MMR and will benefit from molecular monitoring. There is a strong correlation between certain BCR-ABL1 levels and the cytogenetic response, which means that molecular monitoring may act as a surrogate for cytogenetic response,
but only if the BCR-ABL1 values are converted to the international reporting scale. Furthermore, improvements in the limit of BCR-ABL1 detection and reduction of in…
More
Posted by rob on under Uncategorized |
In conclusion, PTEN could modulate
the function of VEGF/VEGFR signaling pathway down-regulation of Akt phosphorylation and that PTEN would be a candidate target
to be addressed for inhibiting angiogenesis along with the treatment of myeloid leukemia.
Content Type Journal ArticlePages 1-9DOI 10.1007/s12032-011-9867-2Authors
Cheng Zhiyong, Department of Hematology, The First Hospital of Baoding, 966 Baihua Road, 050000 Baoding, ChinaLiang Wentong, Department of Hematology, The First Hospital of Baoding, 966 Baihua Road, 050000 Baoding, ChinaYang Xiaoyang, Department of Hematology, Affiliated Haikou Hospital, Central South University, Haikou Municipal Hospital, 43# People’s Road Haidian Island, 5702083 Haikou, ChinaPan Ling, Department of Hematology, West China Hospital, Sichuan Un…
More
Posted by rob on under Uncategorized |
AbstractDisease overview:Polycythemia vera (PV) and essential thrombocythemia (ET) are myeloproliferative neoplasms primarily characterized by erythrocytosis and thrombocytosis, respectively. Other disease features include leukocytosis, splenomegaly, thrombohemorrhagic complications, vasomotor disturbances, pruritus, and a small risk of disease progression into acute leukemia or myelofibrosis.Diagnosis:Diagnosis is based on JAK2 mutation status (PV and ET), serum erythropoietin (Epo) level (PV), and bone marrow histopathology (ET). The presence of a JAK2 mutation and subnormal serum Epo level confirm a diagnosis of PV. Differential diagnosis in ET should include chronic myelogenous leukemia and prefibrotic myelofibrosis.Risk stratification:Current risk stratification in PV and ET is design…
More
Posted by rob on under Uncategorized |
Abstract Cancer chemotherapy was introduced at the same time as antibacterial chemotherapy but has not been nearly such a success.
However, there is a growing optimism in oncology today due to the introduction of several more or less target-specific drugs
as complements to the conventional cytotoxic drugs introduced half a century ago. The success in the treatment of chronic
myelogenous leukemia by imatinib, inhibiting the bcr-abl-activated tyrosine kinase and thereby interrupting the signal transduction
pathways that lead to leukemic transformation with impressive survival benefit, has paved the way for this new optimism. Another
success story is the introduction of trastuzumab in breast cancers overexpressing the HER-2 receptor. In contrast, there has
been little progres…
More
Posted by rob on under Uncategorized |
Abstract The introduction of tyrosine kinase inhibitors (TKIs) has changed the landscape of therapy for chronic myelogenous leukemia
(CML). Once considered an incurable malignancy, CML now has become a manageable chronic condition. Despite the great advances
that imatinib has brought to the treatment of CML, some patients still develop resistance to imatinib and other TKIs, such
as dasatinib and nilotinib. Furthermore, none of the clinically available TKIs is capable of eradicating leukemia stem cells
and therefore curing CML. Several new compounds have been developed in recent years in an attempt to manage TKI-resistant
CML. These include third-generation TKIs (ponatinib, danusertib) and even old compounds such as omacetaxine, which were developed
before imatinib and now …
MedWorm Message: Watch the new MedWorm demo and find out how to get all the very latest, relevant, organized information daily!
More
Posted by rob on under Uncategorized |
This study provides support that FoxO3 is a good biomarker for BCR-ABL-mediated leukemogenesis. Additionally, proteasomal inhibition by bortezomib may be a promising therapeutic option in Philadelphia-positive ALL, where FoxO3 is downregulated.
PMID: 21282974 [PubMed - as supplied by publisher] (Source: Cancer Biology and Therapy)
More
